Goodwin Procter LLP advised AbCellera Biologics Inc. on the deal. AbCellera Biologics Inc. (Nasdaq: ABCL) announced its initial public offering of 27,772,500 common shares at a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
